Welcome to our dedicated page for Cardiac Biotech Solutions news (Ticker: CBSC), a resource for investors and traders seeking the latest updates and insights on Cardiac Biotech Solutions stock.
Cardiac Biotech Solutions, Inc. (CBSC) is a medical technology company that regularly issues news updates about its non-invasive ambulatory cardiac monitoring products, regulatory milestones, and international distribution activities. Its disclosures focus on the MyCardia AT and CardioHolter AT cardiac event monitoring platforms, which combine wearable devices with AWS Cloud-based connectivity and mobile applications.
News coverage for CBSC often highlights regulatory approvals and submissions, such as FDA clearance for MyCardia AT in the United States and a Medical Device License from Health Canada for the CardioHolter AT in Canada. The company also reports on progress toward regulatory clearance in China through collaborations with licensed NMPA medical device manufacturers and hospital-based clinical field testing.
Investors and healthcare observers following CBSC’s news can expect announcements about distribution agreements and purchase orders in key markets. Recent releases have described exclusive distribution arrangements with partners in Canada, Central America, and South America, as well as initial purchase orders for thousands of devices that support the company’s combined device sales and recurring rental revenue model.
Additional CBSC news items address corporate developments, including the company’s name change from CB Scientific, Inc. to Cardiac Biotech Solutions, Inc., voluntary delisting from the OTCQB Venture Market while continuing to trade on the OTC Pink Open Market, and updates on financing efforts and technology initiatives. For readers interested in how remote cardiac monitoring technologies are being deployed across multiple regions and regulatory environments, the CBSC news feed provides ongoing insight into the company’s product launches, partnerships, and strategic steps in the ambulatory cardiac monitoring space.
CB Scientific (OTCQB: CBSC) has announced an exclusive 5-year distribution agreement with Your Heart Protector Corp. in Canada. This agreement will allow Your Heart Protector to market CBSC's non-invasive cardiac monitoring products and provide related services. The partnership includes developing cloud-based software and mobile applications, as well as facilitating regulatory approvals for the myCam 1.1 device. CBSC is also working on obtaining FDA clearance for myCam 1.1 to expand its market reach. The company is committed to keeping investors updated on future developments.
CB Scientific (OTCQB:CBSC) has completed regulatory testing for its enhanced myCam cardiac event monitor and submitted a 510(k) application to the FDA for market clearance. The updated design offers reduced power consumption, improved signal quality, and superior materials that cut component lead times by over 50%. The company expects FDA feedback within 90 to 120 days. Following clearance, CBSC aims to market the device in the U.S. and internationally, including Asia and Latin America, enhancing its competitive position in the cardiac monitoring market.
CB Scientific, Inc. (CBSC) has announced a manufacturing partnership with Shenzhen Pump Medical Co., Ltd. to produce its myCam cardiac monitoring device and related software in China. This agreement recognizes Shenzhen Pump as the official manufacturer, compliant with local regulatory standards. CBSC's myCam has demonstrated high performance with over 2.1 million patient interactions and a 99+% efficiency rate in trials. The collaboration aims to expedite the regulatory approval process by the National Medical Products Administration (NMPA).
CB Scientific, Inc. (OTCQB:CBSC) has announced it has entered the regulatory testing phase for its enhanced myCam cardiac event monitoring device, aiming for FDA 510(k) clearance. The new myCam features improved power consumption, lead wire shielding, signal quality, and cost-effective sourcing, maintaining core functionalities while enhancing market competitiveness. Expected submission for FDA approval is imminent, with product delivery plans for Asia, Latin America, and the Middle East upon clearance.
CB Scientific has appointed James Ott as the new Chief Technology Officer, effective immediately. With over 28 years of experience in ambulatory ECG and clinical research, Ott aims to drive technological innovation and business expansion. His extensive background includes leadership roles in product development, regulatory compliance, and significant contributions to U.S. patent submissions. The company, which specializes in non-invasive cardiac monitoring products, expresses confidence in Ott's ability to enhance investor value and improve healthcare solutions.
CB Scientific has successfully uplisted from the OTC Pink Sheets to the OTCQB Venture Market, starting April 6, 2022. This transition is expected to enhance transparency and liquidity for shareholders. CEO Charles Martin stated this achievement will broaden the company's investor outreach. The OTCQB is recognized by the SEC and mandates companies to maintain current disclosure filings and audited financial statements. Additionally, CB Scientific is planning a corporate name change and relocating its domicile to Nevada to leverage favorable tax laws.
CB Scientific announced the successful completion of its annual audit by MaloneBailey, LLP, adhering to PCAOB standards. This milestone positions the company strongly for an uplisting to the OTCQB Venture Market, expected to enhance investor benefits through higher reporting standards and improved analyst coverage. The company is also set to implement corporate changes, including a name change and relocation to Nevada, to facilitate future fundraising and a potential listing on the Nasdaq Capital Markets. These developments follow a shareholder mandate from a recent special meeting.
CB Scientific, Inc. (CBSC) successfully held its Special Meeting of Stockholders on January 14, 2022, achieving approximately 73% approval for all five proposals. The approved measures include reincorporating the company from Oregon to Nevada and renaming it Cardiac Biotech Solutions, Inc.. Management emphasizes this endorsement is crucial for pursuing future business goals and positions the company for a possible Nasdaq listing. The increase in common shares and potential reverse stock split will help maintain compliance with listing standards.
CB Scientific, Inc. (CBSC) will hold a Special Meeting of Stockholders on January 14, 2022, at 10:00 a.m. EST in Columbus, Ohio, focusing on pivotal corporate changes. Key proposals include a name change to better reflect business direction, relocating for favorable tax laws, increasing authorized shares for fundraising, and ratifying the 2021 Omnibus Stock Incentive Plan to attract talent. These measures aim to position CBSC for a potential Nasdaq listing. The record date for stockholders eligible to vote is December 23, 2021.
CB Scientific, Inc. (OTC PINK:CBSC) has initiated the Beta testing phase for its upgraded My-Cam cardiac event monitor. The new design boasts enhanced power consumption, improved lead wire shielding, and better signal quality, all while reducing costs. With increasing demand for the My-Cam device, the company aims to address supply chain challenges effectively. Following successful Beta testing, CBSC plans to enter Pre-production testing soon. The company will keep stakeholders informed of further developments through press releases and regulatory filings.